Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03846362
Other study ID # NCPHOI-2018-05
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 1, 2019
Est. completion date January 2025

Study information

Verified date March 2023
Source Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Contact Irina Kalinina
Phone +7 495 287 65 70
Email oml-registration@fnkc.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics. Patients with initially high-risk group and those with high MRD after 2 initial courses of chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem cells from Human Leucocyte Antigen (HLA) matched or haploidentical family donors.


Description:

Genetic alterations in acute myeloid leukemia (AML) clone are well known prognostic risk factors of AML relapse. Standard risk group includes favorable t (15;17) (q22; q21) and inv (16)/t (16;16). High-risk patients have a complex karyotype rearrangement (3 and more), inversion of the long arm in 3rd chromosome and EVI1 gene rearrangement, monosomy 5 and 7, translocations involving KMT2A gene and several rare translocations. All other genotype alterations attributed to the moderate risk group. Besides genetic factors, detection of the minimal residual disease (MRD) after initial chemotherapy and its decrease rate after 1st postremission chemotherapy with high dose Cytarabine and anthracyclines, plays a crucial role in the development of the morphologic relapse. Patients with PCR-MRD<0,1% after 2 courses of chemotherapy have a 30% or less risk of relapse, while PCR-MRD>0,1% - over 70%. In the clinical trial investigators are planning to measure MRD either by immune-phenotype, or PCR methods, in 3 check-points and it will be one of decision-making control parameter for the optimal therapy tactics. Patients with initially high-risk group and those with high MRD after 2 initial courses of chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem cells from HLA- matched or haploidentical family donors.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date January 2025
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: 1. de novo acute myeloid leukemia 2. signed informed consent Exclusion Criteria: diagnosis of: Fanconi anemia, acute promyelocytic leukemia, MDS, JMML, AML as secondary malignancy, Dawn syndrome.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
HSCT
allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2>0,1% and initial intermediate risk

Locations

Country Name City State
Russian Federation Regional Children's Clinical Hospital ? 1 Ekaterinburg Sverdlovsk Oblast
Russian Federation Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology Moscow

Sponsors (2)

Lead Sponsor Collaborator
Federal Research Institute of Pediatric Hematology, Oncology and Immunology Physicians, Innovations, Science for Children Fund

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary relapse-free survival (RFS) relapse-free survival from date of diagnosis till date of relapse, or date of death (whichever comes first) or date of last follow up 1 year
Secondary overall survival (OS) 1 year
Secondary event-free survival (EFS) Event=relapse/nonresponse, death or second malignancy 2 years
Secondary The proportion of of patients with severe adverse effects The proportion of of patients with severe adverse effects of therapy according to CTCAE (ver 4.3) 6 months
Secondary The proportion of of patients with severe infections The proportion of of patients with severe infections: number of episodes, grade, after each course of chemotherapy 1 month
Secondary The proportion of of patients with severe cardiotoxicity The proportion of of patients with severe cardiotoxicity: number of episodes and %EF by echocardiogam 1 year
Secondary MRD dynamic MRD (IFT and/or PCR) dynamic between check-points 1 months
Secondary MRD specificity and sensitivity MRD specificity and sensitivity in relapse prognosis 1, 2, 3 months
Secondary Cumulative incidence of relapse competing event - death in CR 6 months, 1 year
Secondary Cumulative incidence of transplant-related mortality for transplanted patients 6 months after HSCT
Secondary Cumulative incidence of aGvHD II-IV grade for transplanted patients 100 days after HSCT
Secondary Cumulative incidence of cGvHD for transplanted patients 1 year after HSCT
See also
  Status Clinical Trial Phase
Recruiting NCT05519384 - Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia Early Phase 1